Literature DB >> 10928984

Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation?

S H Hong1, F G Ondrey, I M Avis, Z Chen, E Loukinova, P F Cavanaugh, C Van Waes, J L Mulshine.   

Abstract

High levels of prostaglandins are produced in human oropharyngeal carcinoma (OPC). Five human OPC cell lines tested expressed both isoforms of cyclooxygenases (COX). The pan-COX inhibitor ketorolac continuously and significantly decreased PGE(2) production and IL-6 and IL-8 levels in all OPC cell lines tested, but did not affect IL-1alpha, GM-CSF levels, or in vitro tumor cell growth. In contrast, ketorolac reduced OPC growth in vivo. The OPC cell lines used express the IL-6 receptor, and IL-6 stimulation of these cells causes transduction to occur via STAT3 pathway activation. Coincubation with OPC cell lines with conditioned medium from a TPA-exposed HL-60 cells stimulated growth proportional to the IL-6 levels measured in the conditioned medium. This growth effect was specifically inhibited by anti-IL-6 antibody. These results are consistent with cytokine products of inflammatory cells having paracrine growth effects on OPC. If chronic inflammation plays a role in promoting the development of OPC, this mechanism may also apply to other epithelial tumor systems modulated by COX activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928984     DOI: 10.1096/fj.14.11.1499

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  18 in total

1.  Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.

Authors:  Lauren Averett Byers; F Christopher Holsinger; Merrill S Kies; William N William; Adel K El-Naggar; J Jack Lee; Jianhua Hu; Adriana Lopez; Hai T Tran; Shaoyu Yan; Zhiqiang Du; K Kian Ang; Bonnie S Glisson; Maria Gabriela Raso; Ignacio I Wistuba; Jeffrey N Myers; Waun-Ki Hong; Vali Papadimitrakopoulou; Scott M Lippman; John V Heymach
Journal:  Mol Cancer Ther       Date:  2010-06-08       Impact factor: 6.261

Review 2.  Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling.

Authors:  Robert Vander Broek; Grace E Snow; Zhong Chen; Carter Van Waes
Journal:  Oral Oncol       Date:  2013-10-28       Impact factor: 5.337

3.  Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer.

Authors:  Carter Van Waes; Clint T Allen; Deborah Citrin; David Gius; A Dimetrios Colevas; Nancy A Harold; Susan Rudy; Liesl Nottingham; Christine Muir; Zhong Chen; Anurag K Singh; Janet Dancey; John C Morris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-30       Impact factor: 7.038

4.  Salivary IL-6 levels in oral leukoplakia with dysplasia and its clinical relevance to tobacco habits and periodontitis.

Authors:  Mohit Sharma; Indira Bairy; Keerthilatha Pai; Kapaettu Satyamoorthy; Shailendra Prasad; Barry Berkovitz; Raghu Radhakrishnan
Journal:  Clin Oral Investig       Date:  2010-06-19       Impact factor: 3.573

5.  The Role of the NF-kappaB Transcriptome and Proteome as Biomarkers in Human Head and Neck Squamous Cell Carcinomas.

Authors:  Zhong Chen; Bin Yan; Carter Van Waes
Journal:  Biomark Med       Date:  2008       Impact factor: 2.851

6.  Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.

Authors:  Francisco G Pernas; Clint T Allen; Mary E Winters; Bin Yan; Jay Friedman; Bhavana Dabir; Kunal Saigal; Gerhard S Mundinger; Xiaojiang Xu; John C Morris; Katherine R Calvo; Carter Van Waes; Zhong Chen
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

7.  Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer.

Authors:  Jordi Tauler; James L Mulshine
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

8.  COL11A1 activates cancer-associated fibroblasts by modulating TGF-β3 through the NF-κB/IGFBP2 axis in ovarian cancer cells.

Authors:  Yi-Hui Wu; Yu-Fang Huang; Tzu-Hao Chang; Chien-Chin Chen; Pei-Ying Wu; Soon-Cen Huang; Cheng-Yang Chou
Journal:  Oncogene       Date:  2021-06-11       Impact factor: 9.867

9.  The Proteomic Landscape of Growth Factor Signaling Networks Associated with FAT1 Mutations in Head and Neck Cancers.

Authors:  Zhengjia Chen; Chao Zhang; Jianhong Chen; Dongsheng Wang; Jieqi Tu; Carter Van Waes; Nabil F Saba; Zhuo G Chen; Zhong Chen
Journal:  Cancer Res       Date:  2021-06-24       Impact factor: 13.312

10.  Stimulated monocyte IL-6 secretion predicts survival of patients with head and neck squamous cell carcinoma.

Authors:  John-Helge Heimdal; Kenneth Kross; Beate Klementsen; Jan Olofsson; Hans Jørgen Aarstad
Journal:  BMC Cancer       Date:  2008-01-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.